NYSE:TEVAPharmaceuticals
Teva (TEVA): Assessing Valuation After a 65% Three‑Month Share Price Surge
Teva Pharmaceutical Industries (TEVA) has quietly turned into one of the market’s stronger comeback stories, with shares up roughly 65% over the past 3 months and more than 40% over the past year.
See our latest analysis for Teva Pharmaceutical Industries.
That surge has been underpinned by solid execution, with Teva’s 30 day share price return of 22.04% and a three year total shareholder return of 230.95%. This suggests momentum is building as investors re rate its turnaround potential.
If...